A nurse is assessing a client who has impaired mobility. The nurse should monitor the client for a pressure injury due to which of the following factors?

Choice A reason: The Healthy People initiative does not primarily focus on utilizing health data from the past 20 years. While it uses data to inform goals, its core purpose is to set forward-looking, evidence-based health objectives for the U.S. population. Historical data supports trend analysis, but the initiative emphasizes decade-long goals to improve health outcomes, not retrospective data collection.

Choice B reason: The Healthy People initiative, led by the U.S. Department of Health and Human Services, establishes measurable health objectives for Americans every decade. It sets evidence-based goals to improve public health, reduce disparities, and promote disease prevention and health promotion, addressing issues like chronic diseases, maternal health, and access to care, tailored to national health priorities.

Choice C reason: The Healthy People initiative does not focus solely on nonmodifiable risk factors, such as genetics or age. Instead, it emphasizes modifiable risk factors, like smoking or physical inactivity, to promote preventable health improvements. While it acknowledges nonmodifiable factors, its objectives target actionable interventions to enhance population health outcomes across diverse communities.

Choice D reason: The Healthy People initiative is U.S.-centric and does not primarily track global health trends. Its focus is on national health priorities, setting objectives to address domestic health challenges, such as obesity or mental health. Global health trends may inform contextual understanding, but the initiative’s scope is limited to improving health outcomes within the United States.

Choice A reason: Sucralfate is a mucosal protectant that forms a gel-like barrier over gastric ulcers, shielding them from acid and pepsin. It does not have antimicrobial properties to prevent opportunistic infections, which are typically managed by antibiotics or antifungals targeting pathogens like Candida or Pneumocystis in immunocompromised patients.

Choice B reason: Sucralfate acts locally in the gastrointestinal tract, coating ulcerated mucosa to promote healing. It has no systemic effects on ocular structures or neural pathways involved in vision. Impaired vision may result from conditions like cataracts or glaucoma, which require specific ophthalmic treatments, not mucosal protectants.

Choice C reason: Sucralfate’s therapeutic effect involves forming a protective barrier over gastric or duodenal ulcers, reducing irritation from stomach acid and pepsin, thus alleviating gastrointestinal pain. This local action promotes ulcer healing and symptom relief, making pain reduction a direct indicator of its efficacy in peptic ulcer disease management.

Choice D reason: Sucralfate does not affect glucose metabolism or insulin secretion. Blood glucose reduction is managed by antidiabetic agents like metformin or insulin, which target pancreatic beta cells or glucose uptake. Sucralfate’s action is confined to the gastrointestinal tract, with no impact on endocrine pathways regulating blood sugar.